Central Veterinary Medicine Joint Stock Company No. 1 (Vinavetco) and Cai Lay Veterinary Pharmaceutical Joint Stock Company (Mekovet), two established Vietnamese veterinary pharmaceutical companies, have merged to form establish Vietnam Veterinary Pharmaceutical Group.
The strategic alliance, which took effect on August 11, 2025, marks more than a merger. It integrates two legacies, two regional powerhouses, and two complementary strengths to build a stronger, more comprehensive organization.
Vinavetco, founded in 1973, brings a strong scientific foundation and strength in injectable drugs and vaccines. Its state-owned infrastructure spans production, distribution, and R&D across northern Vietnam, operating under the motto ‘For Community Health.’
Mekovet, founded in 1990 in southern Vietnam, is known for its innovation and modern technologies. The company excels in premix, soluble powder, injectable antibiotics, and has a broad private distribution network across the region.
Building a leading group with regional reach
The merger creates a modern, unified, and stronger veterinary pharmaceutical ecosystem. This alliance will enhance overall capabilities across R&D, production, and distribution to ensure superior competitiveness in an increasingly demanding and volatile market.
Nationwide distribution will be streamlined, creating a unified network that would improve customer service efficiency, shorten market access time, and boost operational flexibility.
The alliance enhances competitiveness, especially as global corporations are expanding into Vietnam. It allows both brands to leverage their complementary advantages and face global competition with a powerful synergy.
It is also an opportunity to optimize resources, creating a unified organization ready for digital transformation and international expansion.
The long-term goal is clear: build a leading veterinary pharmaceutical group in Vietnam with a strong presence in Southeast Asia.
Vision and roadmap
Vietnam Veterinary Pharmaceutical Group aims to lead the industry. It will adopt a standardized management system under GMP-WHO and ISO 22000 for quality and safety.
It will immediately implement the advanced SAP S/4HANA enterprise resource planning software and invest significantly in key areas including:
- ✅ planning a vaccine manufacturing facility,
- ✅ developing next-generation antibiotics,
- ✅ herbal-based biological products,
- ✅ functional nutrition for livestock,
- ✅ establishing a dedicated R&D innovation center,
- ✅ and expanding international markets.
The launch also marks a new chapter for Vietnam’s veterinary pharmaceutical industry.
David John Whitehead
David John Whitehead, Chairman of Mavin Group, acted as strategic advisor and supporter of the merger, helping shape the vision and organizational model, said:
“We are honored to accompany Vinavetco and Mekovet in this highly strategic transformation. This unification not only creates a stronger organization but also demonstrates a commitment to shaping the future of Vietnam’s livestock industry with comprehensive, sustainable, and forward-looking solutions. I believe this will lay the foundation for Vietnam Veterinary Pharmaceutical Group to lead the domestic market and gradually conquer international markets.”
Vietnam’s livestock and aquaculture sectors demand higher standards for quality, safety, and efficiency. The new group is positioned to lead with innovation, resilience, and regional integration.
With a solid foundation, strategic vision, and advisory support from Mavin Group, Vietnam Veterinary Pharmaceutical Group is poised to become a new symbol of sustainable development.